SPOTLIGHT: The top five VC deals of 2007


Venture capital is the lifeblood of up-and-coming biotechs. In order to interest investors and keep the money coming in, biotechs must have a strong vision, promising pipeline and a management team that can guide a company through the rigorous drug development process. For a look at which biotechs have gained the most attention this year, check out the five promising companies that raised the most money in the first half of 2007. List

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.